ORPH.L Regulatory News (ORPH)

30 March 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Contracts worth EUR4.1m signed with US Biotech client

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces today the signing of new contracts worth over €4.1m with a leading US based Biotechnology client.

The deals are an extension of an existing contract which has doubled in size and the award of a new clinical trial to the value of €2.7m. These Phase II clinical trials, that evaluate the efficacy of a pioneering drug in the areas of Oncological hematology and Respiratory, will run over 24 months in multiple European and US sites. Venn has extensive experience in the management of Phase II trials with a history of over 25 years running studies throughout Europe.

Speaking about the agreement, Venn CEO, Tony Richardson stated: "The signing of these contracts is a compliment to all the team at Venn who have been diligently working with this client since last year. It reinforces our commitment to consistently deliver excellent international services and our ability to win larger projects from global clients. We are clearly seeing tangible results from our key investments over the course of 2014."

Enquiries:

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.